CIGLi001-A-8

The cell line is not validated yet.

General

Cell Line

hPSCreg name CIGLi001-A-8
Cite as:
CIGLi001-A-8
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 23rd January 2026
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator IRCCS - Istituto di Ricerche Farmacologiche Mario Negri (IRFMN)
Owner IRCCS - Istituto di Ricerche Farmacologiche Mario Negri (IRFMN)
Derivation country Italy

General Information

* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity Hispanic

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history no

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
Passes test for quality control as mentioned by supplier
vcf File:
802 30F datasheet.pdf
The company, SYNTHEGO, that is supplying the cell line to us, mentions that quality control assessment is done and sequence validation data can be provided upon request

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA114652490

Ethics

Also have a look at the ethics information for the parental line CIGLi001-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line CIGLi001-A.

Reprogramming method

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Accutase
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
TRA 1-60
Yes
TRA 1-81
Yes
SSEA-3
Yes
SSEA-4
Yes
NANOG
Yes
Score:
Marker Present Absent
mCpG
OCT4
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
alpha fetoprotein
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
smooth muscle actin
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
tubulin beta 3 class III
Unknown

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease
B2M beta-2-microglobulin (target)
Gene knock-out
15q21.1
CRISPR-associated (CRISPR/Cas) System
CIITA – class II major histocompatibility complex transactivator (target)
Gene knock-out
16p13.13
CRISPR-associated (CRISPR/Cas) System